Section 361 vs 351 FDA Compliance for Biologics

Section 361 human tissue products are exempt from premarket FDA approval when processed strictly for minimal manipulation and homologous use, whereas Section 351 biologics require Investigational New Drug (IND) or Biologics License Applications (BLA) due to systemic or metabolic functions. For practices procuring tissue biologics, verifying vendor compliance under 21 CFR 1271 protects clinical inventory from unapproved drug classifications. This guide outlines the structural criteria separating 361 and 351 regulatory pathways to streamline compliance and vendor auditing.

Understanding the Regulatory Framework: Section 361 vs Section 351

The regulatory oversight of human cells, tissues, and cellular and tissue-based products (HCT/Ps) is governed under Title 21 of the Code of Federal Regulations (CFR), specifically Part 1271, alongside the Public Health Service (PHS) Act. Understanding which section governs a specific tissue product determines the legal requirements for processing, marketing, procuring, and clinical application.

Section 361 of the PHS Act applies to lower-risk tissue products. To qualify under Section 361, a product must meet all criteria outlined in 21 CFR 1271.10(a). These products are not subject to pre-market review, approval, or licensing by the FDA. Instead, manufacturers must register their establishment, list their products, and adhere to current Good Tissue Practice (cGTP) requirements focused primarily on donor screening and communicable disease prevention.

Section 351 of the PHS Act applies to biological products that do not meet all criteria of Section 361. Because these products carry a higher potential risk profile or altered biological action, they are regulated as biological drugs, devices, or biological products. Section 351 products require formal pre-market review through a Biologics License Application (BLA) or must be investigated under an active Investigational New Drug (IND) application before commercial distribution.

Key Criteria Determining Section 361 Eligibility

To maintain compliance under Section 361 without triggering Section 351 biological drug requirements, an HCT/P must satisfy four specific regulatory tests:

1. Minimal Manipulation: Processing cannot alter the original relevant characteristics of structural tissue or the biological characteristics of non-structural tissue.
2. Homologous Use: The product must perform the same basic function or functions in the recipient as it performed in the donor tissue.
3. No Combination: The product cannot be combined with another article, device, or drug, except for water, crystalloids, or specific sterilizing or preserving agents.
4. Systemic Effect and Metabolic Activity: The product must not have a systemic effect and must not depend upon the metabolic activity of living cells for its primary function (unless intended for autologous use, or allogeneic use in first- or second-degree blood relatives).

Section 361 vs Section 351 Regulatory Comparison

When evaluating tissue products for practice procurement and clinical integration, practice administrators can refer to the following compliance comparison list:

• Regulatory Pathway: Section 361 requires facility registration (FDA Form 3356) and cGTP compliance; Section 351 requires formal IND/BLA pre-market approval.
• Processing Level: Section 361 mandates minimal manipulation (e.g., dicing, rinsing, freezing); Section 351 encompasses extensive manipulation, such as enzymatic digestion or cell expansion.
• Intended Application: Section 361 requires strict homologous use matching native tissue function; Section 351 applies to non-homologous uses or novel disease treatment indications.
• Cellular Viability: Section 361 relies on non-systemic, passive structural or matrix support; Section 351 includes living cellular therapies acting systemically or metabolically.
• Promotional Marketing: Section 361 claims must focus strictly on tissue repair or replacement without drug-like disease treatment claims; Section 351 products can market specific clinical efficacy once approved via BLA.

Clinical vs Operational Considerations for Practice Managers

Clinical Perspective: Patient Selection and Treatment Rationale

For treating clinicians, navigating regulatory boundaries requires aligning patient care protocols with established tissue characteristics. When utilizing biologics such as structural tissue allografts, amniotic matrix, or autologous blood concentrates, clinicians must ensure the clinical objective aligns with homologous use definitions.

For example, applying structural allografts to cushion or cover damaged connective tissue aligns with standard structural application expectations. Conversely, administering tissue products for systemic non-homologous conditions or marketing tissue therapies as definitive treatments for chronic organic diseases shifts the product into Section 351 classification. Clinicians should continuously consult professional literature and guidance published in regulatory updates and publications to maintain compliance.

Operational Perspective: Procurement, Sourcing, and Audit Readiness

For practice managers and procurement leaders, administrative oversight centers on vendor vetting and regulatory risk management. Integrating regenerative solutions into daily clinic operations requires rigorous documentation workflows to verify that suppliers maintain strict regulatory standards.

Practice managers must verify that every distributor or tissue bank supplies complete donor screening verification, lot-specific Certificates of Analysis (CoA), and proof of FDA establishment registration. Sourcing unverified or improperly classified tissue exposes a practice to legal liability, warning letters, and operational disruption. Establishing standardized compliance protocols and consulting resource guides such as our FAQ section helps simplify administrative oversight.

What This Means for Your Practice

Ensuring compliance with FDA regulations regarding Section 361 and 351 biologics requires proactive oversight across clinical, procurement, and administrative functions. Practice managers should execute the following actionable steps:

1. Audit Current Biologic Inventory: Review all tissue products currently stocked in your clinic. Verify that each product maintains documented compliance under 21 CFR 1271 criteria.
2. Request Full Vendor Compliance Packs: Demand vendor documentation including FDA Form 3356 registration, cGTP compliance statements, and lot-specific Certificates of Analysis prior to ordering.
3. Review Practice Marketing Materials: Audit website content, social media channels, and patient consent forms. Eliminate any drug-like disease treatment claims or unapproved therapeutic guarantees.
4. Establish Storage and Chain of Custody Protocols: Maintain precise logbooks recording tissue lot numbers, expiration dates, patient charts, and storage temperature logs.
5. Educate Clinical and Administrative Teams: Conduct periodic training updates for regenerative medicine doctors and clinical personnel to reinforce homologous use guidelines and documentation procedures.

Ensuring Regulatory Compliance with DRS

Navigating regulatory landscapes while expanding clinical service lines requires trusted supply partners committed to full regulatory transparency. Dallas Regenerative Solutions works with licensed practices to supply compliant tissue allografts, advanced devices, and operational guidance tailored to clinical efficiency.

To discuss your practice’s procurement needs or consult with our team on regulatory documentation, contact us today at Dallas Regenerative Solutions.